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Abstract
Background: Consent processes for clinical trials involving HIV prevention research have generated considerable
debate globally over the past three decades. HIV cure/eradication research is scientifically more complex and
consequently, consent processes for clinical trials in this field are likely to pose a significant challenge. Given that
research efforts are now moving toward HIV eradication, stakeholder engagement to inform appropriate ethics
oversight of such research is timely. This study sought to establish the perspectives of a wide range of stakeholders
in HIV treatment and research to inform consent processes for cure research.
Methods: In total, 68 South African stakeholders participated in two qualitative research modalities. In-depth
interviews (IDIs) were conducted with a purposive sample of 42 individuals - audiotaped with consent. Twenty-six
stakeholders participated in three focus group discussions (FGDs). Thematic analysis of transcribed IDIs and FGDs
was conducted.
Results: The majority of respondents indicated that there could be unique challenges in HIV cure research
requiring special attention. In particular, given the complexity of cure science, translation of concepts into lay
language would be critical for potential participants to adequately appreciate risks and benefits in early phase
research with experimental interventions. Furthermore, to aid understanding of risks and benefits against a
background of desperation for a cure, specially trained facilitators would be required to assist with a psychological
assessment prior to consent to avoid curative misconceptions. Long-term participant engagement to assess
durability of a cure would mean that the consent process would be prolonged, necessitating annual re-consent.
Building trust to maintain such long-term relationships would be critical to retain study participants.
Conclusion: Unique consent requirements for cure research in South Africa would include significant efforts to
maximise understanding of trial procedures, risks and the need for long-term follow-up. However, the psychological
dimension of cure must not be underestimated. Beyond an understanding of cure science, the emotional impact of
HIV cure advances the discourse from cure to healing. Consequently, the consent process for cure research would
need to be enhanced to include psychological support and counselling. This has several important implications for
research ethics review requirements for consent in HIV cure research.
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Background
The science of HIV cure research is complex. Poten-
tial cure strategies include the use of highly active
antiretroviral therapy (HAART) during acute infec-
tion, latency-reversing compounds, gene editing, the
administration of broadly neutralizing antibodies,
therapeutic vaccines, and/or various combinations of
the above. Some of these strategies will include ana-
lytical treatment interruption [1]. At least a hundred
early phase trials have been completed in the United
States relating to various aspects of HIV cure research
[2]. Approximately a hundred additional trials are in
progress [3]. In South Africa, cure research started in
children in 2017 using the strategy of very early
treatment (personal communication). Data from this
research has not been published as yet.
Historically, research on most other diseases has been
framed as “treatment” research, and not cure [4] In
diseases like Syphilis, treatment evolved into cure [5, 6].
Experimentation occurred on a trial and error basis and
not in large scale randomised controlled “cure” trials as
is currently the plan for HIV eradication.
The uniqueness of AIDS ‘cure’ research does not lie in
the meticulous ethical underpinning of the research as
described elsewhere, such as the quest for authentic in-
formed consent, problematic as it may be. To an extent
it lies in the nature, epidemiology and politicisation of
the disease and consequent trial design, but perhaps
even more in the socioeconomic situatedness, extreme
vulnerability and disempowerment of likely participants
in developing countries and the value laden societal
judgements and stigmatisation of those afflicted by HIV
and AIDS.
This vulnerability has already been exploited by several
offers of cure in the past. Such offers either pre-dated
the availability of antiretrovirals or coincided with the
experience of severe adverse effects by patients on anti-
retroviral treatment. It is unsurprising that the concept
of “HIV cure” in South Africa is contentious given the
wide range of illegitimate and fraudulent cures for HIV
that have been advanced over the past three decades.
Such “cures” include herbal, traditional and chemical
compounds offered to vulnerable patients by charlatans,
politicians, healthcare workers and scientists, both local
and foreign [7–12].This complicates, confounds and un-
dermines the legitimacy of the current scientific agenda
of HIV eradication.
A wide range of ethical considerations have recently
emerged in the limited literature on HIV cure research
[13–18].In particular, concerns have been raised about
the consent process - how will trial information be com-
municated to participants and patients, what will
motivate participation in potentially high risk research
with little prospect of direct benefit and how will
understanding of trial procedures, risks and benefits be
assured? [2, 19, 20]. Analytical treatment interruption
evokes concerns about viral rebound and increases the
risk profile associated with HIV eradication studies [1].
In addition, the language used in communicating “cure”
as a concept is challenging in many respects [21]. Differ-
entiating between a “functional” cure and a “sterilizing”
cure is of paramount importance in the consent process
[22]. Some of these ethical concerns have been raised in
the context of Hepatitis B cure research in resource rich
settings. While HIV is a multisystem disease, hepatitis
affects the liver primarily, so scientifically, the research
challenges are different. Ethical concerns may be similar
in some respects but differ in others [23].
The ethical concerns raised by HIV cure research are
likely to be exacerbated in resource poor settings, where
HIV cure research has not started in earnest, and where
consent processes on less complex research are already
challenging [24–27] . While significant efforts have been
invested in developing consent processes and tools for
HIV prevention and treatment research in South Africa
over the past three decades [28–31], work on HIV cure
consent processes remains in its infancy [26, 32]. Given
the high burden of disease due to HIV in South Africa, a
“cure” is imperative as a medical breakthrough. How-
ever, the history of HIV research in this country has
taught us that engaging with a broad range of stake-
holders via formative research ahead of the science is
important to establish perceptions around how “cure” is
understood, how understanding of complex science can
be facilitated and how risk assessment can be facilitated
so that informed consent is authentic. This is particu-
larly important against the historical context of illegitim-
ate cures in South Africa [7–12].
As part of a broader study on the intended and unin-
tended consequences of HIV cure research, this paper
specifically explores the perspectives of multiple, diverse
stakeholder groups on the anticipated challenges in HIV
cure research in South Africa to guide the development
of consent processes and protocol review by research
ethics committees (RECs).
Methods
In order to explore some of the pertinent intended and
unintended consequences of HIV cure research in South
Africa, we conducted individual in-depth interviews
(IDIs) and focus group discussions (FGDs) with a broad
range of stakeholders with experience of working or
living with HIV in South Africa.
Sample
Using purposive or strategic sampling, making a deliberate
choice of respondents to ensure coverage of as full a range
of characteristics of interest as possible [33, 34]; we
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selected respondents from a range of stakeholder categor-
ies to elicit diverse commentary on the potential ethical is-
sues around HIV cure research. The respondents included
scientists involved in different stages of cure research,
from the laboratory to clinical trials, clinical professionals
from academic, public and private health services, social
scientists who work in the area of HIV, representatives
from RECs, religious figures with a community profile, ac-
tivists working in HIV, medical students and patients. This
provided a wide range of potential opinions within the
South African context. Many of the respondents have
international profiles which we feel will enhance the value
of the results to contexts outside of South Africa.
The total sample for this project included 83 stake-
holders who were contacted telephonically or via email.
Of these, 42 agreed to be interviewed (IDIs) and 15 de-
clined participation or did not respond to a request for an
interview (IDIs). All participants who were approached to
participate in FGDs, agreed (n = 26). Three FGDs took
place: two with people living with HIV (PLHIV) including
caregivers of children living with HIV, and a third with
medical students.
Material from 14 of the IDIs with HIV experts was
analysed and published previously [32]. This paper
represents the views of 54 participants (28 other HIV stake-
holder groups obtained via IDIs and 26 FGD participants)
and reflects key themes relating to consent specifically that
had not been addressed in the earlier paper.
Fieldwork
The IDIs were conducted by seven researchers in four dif-
ferent cities in South Africa (Cape Town, Johannesburg,
Pretoria and Durban) and two of the seven were involved
in the FGDs. Interviews were conducted after informed
consent was obtained and each lasted approximately 40–
60min. All IDIs were conducted in English and the FGDs
were primarily in English. For interviews with PLHIV and
caregivers, an interpreter was available for isiXhosa and
Afrikaans speaking patients.
The interviewers had diverse professional backgrounds:
bioethicist, lawyer, social scientist, genetic counsellor,
clinician, psychologist and medical scientist. The meth-
odological approach was contextualised as interpretative
research, to achieve a deeper understanding of what the
respondents were saying, and the values and paradigms
that guided their thinking [35, 36]. All interviewers were
trained on the objectives of the study prior to going into
the field and shared a common understanding about the
focus of the interviews. The discussion schedule used for
all interviews included the following broad areas: HIV
Cure Concepts, History of HIV Cure, Cure Research
Ethics, Cure Research participation, Cure Early Imple-
mentation, and Internet Access. The emphasis given to
each section would differ by participants and not all areas
are reported in this paper, as this paper is only part of a
broader study.
The interviews were framed using the following con-
text: interviewers explored perspectives around ethical
and social issues associated with hypothetical functional
and sterilizing “cures”. In either case, a hypothetical
“cure” intervention study to assess impact would require
an extended period of follow-up and monitoring to en-
sure that the “cure” had worked and that all the body’s
reservoirs were cleared of disease. The participants
recruited in such hypothetical trials would include both
those who were newly diagnosed with HIV and those
who had been on HAART for an extended period with a
controlled HIV viral load in the blood. The focus was on
hypothetical adult patients recruited from treatment or
testing clinics in geographically defined communities in
South Africa. The research design assumed was that of a
phase 3 randomised control trial to assess effectiveness
of a new cure intervention. Interviewees understood
that, given the early stage of cure research, many of the
early trials are likely to be unsuccessful and it may take
a while to develop an effective and usable “cure”. This
scenario is analogous to what is happening with microbi-
cide and HIV vaccine research. A plain language fact
sheet was provided to all participants at the start of the
interview, briefly summarising HIV cure concepts and
research, focusing on the information provided above.
Analysis
Recorded interviews were transcribed verbatim. Formal
analysis began two thirds of the way into the data collec-
tion. Two of the interviewers (ZD and CS) took a lead in
developing the codebook based on detailed preliminary
readings of the initial interviews. They also consulted
other members of the team including DS who was
Table of respondents
Laboratory scientists 5
HIV trial researchers 5
Academics 8
Public health administrators 3
Private Health Funders 5
Social scientists 5
Ethics committee members 4
HIV activists 4
Religious leaders 2
Journalists 1
FGD1: Medical Students 6
FGD2: PLHIV 9
FGD3: PLHIV 11
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leading the formal analysis and who had read the
interview transcripts. Emerging themes were discussed
between the principal investigator (KM) and other mem-
bers of the team (DS, CS). To maximise inter-coder
reliability, codes were defined clearly and distinctively.
Three competent coders coded all the transcripts and
reconciled coding discrepancies. The coding was refined
until an acceptable degree of inter-coder reliability was
reached. Throughout this process, codes were reviewed
to assess the necessity of adding additional codes. No
additional codes were added, as all the data fitted into
existing codes; however some definitions were altered as
the coding progressed, to take the full extent of the data
into account. Data analysis was facilitated by using the
software program Nvivo. A contextualised thematic ap-
proach, in which the quotes associated with each theme
are interpreted in terms of the context in which they are
raised [33, 35, 36], was used to interpret the results. DS
lead the analysis but met regularly with CS and KM to
discuss results and check the interpretations made. A
specific separate analysis was not done for each stake-
holder group, as the focus was on finding common
understandings across all the groups. Variation across
the stakeholder groups was noted, especially where one
group took a different stand on a particular issue. Where
this impacted on the discussion, it was noted in the text.
Ethics
This study was approved by the Health Research Ethics
Committees at Stellenbosch University (N13/05/063),
the University of Pretoria (29/2015) and the University
of Cape Town (761/2014). In addition, provincial
approval was obtained where required (Tygerberg
Hospital). All participants signed an informed consent
form stating that they understood the research and that
they agreed both to be interviewed and to audiotaping.
All personal identifying data were removed from the
interviews.
Results
Six main themes emerged from the data. The key discus-
sion focused on the way in which HIV cure research dif-
fered from other clinical trials, and the risks that this
may expose research participants to. The discussion is
framed around the construct that researchers are obliged
to protect participants from dangers that may not be
realised or that are difficult to conceptualise.
The emergent themes are discussed in detail below:
HIV exceptionalism and consent
In any clinical trial, provision of informed consent prior
to enrolment is a pre-requisite to participation. The
standard procedure is well outlined in Good Clinical
Practice (ICH-GCP) guidelines for clinical trials and in
various other research ethics guidelines. A central theme
throughout the interviews was that these guidelines
should direct HIV cure trial research and that some
special additional considerations need to be applied to
ensure complete understanding. There was also concern
that HIV has, at times, been treated as “different”.
All clinical studies should be done exactly the same.
(L = REC member)
I am not too sure why people see it [HIV] as (different);
or what people foresee as an ethical difficulty. I mean as
long as the agent follows the normal process of what
clinical trials do, and the safety considerations of
clinical trials. As long as it follows the normal
processes; I am not quite sure what the ethical
dilemmas even are. (G = public health administrator)
Having said that, the dominant narrative identified
areas within the current requirements that do need
particular attention in the case of HIV cure given the
desperation and vulnerability of many HIV-infected
participants in the South African context:
I think there needs to be a lot more dialogue than
normally would happen. I mean because of all the
attention around the illness. (A= private health funder)
Well, consent is basic …and I think that it is
problematic - to really make sure that people are well
informed … as people may sort of grab at the last
straw to say “Well let’s try it” just out of being
desperate and not really being well informed.
(M = religious leader)
Improving understanding through science translation
Respondents expressed concern over scientifically
complex patient information leaflets and consent
documents:
The lengthier and the more detailed the informed
consent process is, the more likely the patients are
to switch off. So it's easier for them to understand
one page than it is to understand – I mean some
of the pharmaceutical trial informed consent
documents are like mini-theses; and you get tired
just looking at them and they tend to be very
repetitive, not easy to read and all sorts of clauses
which are more designed to protect the researchers
and the sponsor, than... are really of benefit to
patients. (B = academic)
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Likewise, many of the constructs used in the explan-
ation of cure are difficult to understand. For example,
remission has been suggested as a suitable alternative to
the word “cure”. However, it can be difficult to commu-
nicate; metaphors such as talking about remission in
cancer are not necessarily accurate and carry loaded
meanings depending on the person’s experience and
awareness. Very few people, even in research and clinical
settings, fully understand the meaning of the words re-
mission, functional cure or reservoirs, amongst others.
These are all words that cure research uses extensively
and will require accurate, yet simple, explanation.
I've got a PhD and I work in health research; I don't
really know what remission means… and I'm English
speaking; but I still think in our context we have to
deal with many, many issues in clinical trials that
people struggle to understand… but we’ve got to keep
trying. So… who understands randomization; who
understands prophylaxis? (aa = social scientist)
The level of explanation required did vary across the
sample that we interviewed, with some respondents
feeling that the standard GCP requirements were
sufficient with a good assessment of knowledge. Others
argued that a far more detailed profile and assessment of
the readiness of potential participants was necessary.
It would have to be quite an extensive psychological
evaluation on these potential candidates … where it’s
fully explained to them… what the risks are and then
somebody – a psychologist or somebody would have to
determine ″Okay, this patient is fully aware of
everything and he’s in a position – a stable position
where he would happily make this decision, and he can
cope with the consequences. (FGB2 = medical student)
The informed consent is sort of providing the support
framework, so it is the same as when you do any of the
psychological studies that you have built in; that there is
recourse to support. And this – if it’s built in from the
beginning that there are regular check-ups to assess
mental state and understanding. (D = REC member)
A key point raised was that the processes by which
people construct meaning based on what they are told
are poorly understood. As with any other new or differ-
ent construct people may encounter, they tend to recon-
struct it in terms that they understand. This background
knowledge used to construct meaning cannot always be
known by the research team, so achieving informed con-
sent may require an active process to explain the study,
to engage and work with the potential participant until
an adequate level of understanding has been achieved.
The potential for confusion and misunderstanding of the
implications of participation is immense. Participants
may be getting different messages and information from
other healthcare providers during the trial, as well as
from non-medical sources such as friends, traditional
and alternative healers, family members and the media.
We know that memory isn't recall, it's a
reconstruction; so all of this is going to get
reconstructed and changed and reconfigured.
(aa = social scientist)
Communicating risks and benefits accurately
A strong consistent recommendation from respondents
was to refrain from calling these studies “cure” research,
as this creates artificial expectations and may lead to
people consenting without clear understanding. The role
of the trial should be explained as being part of the over-
all development of research on HIV and potential treat-
ment and cures. The actual naming of the trial and its
impact on the virus and the participants’ potential
well-being will differ from trial to trial, but the naming
of the research as the testing of a “cure” has to be
avoided until a much higher level of scientific confidence
exists.
I don’t think you could tell anybody you’re going to
give them an HIV cure. You’re going to say what
you’re looking at is trying to reduce the amount of
HIV in their body; and that you’re working towards a
cure. You certainly can’t put people on the study and
tell them that you’re going to cure them; unless you
know for sure that you’re going to cure them.
(F = HIV researcher)
People are going to have to understand what you
mean by cure. How does that define my life? If I have
to take the drugs plus this other drug, how do I do it?
When do I know about it? When will it be
determined that I’m cured? What do I have to do
afterwards? (1 = HIV activist)
The inherent risks involved in participation must be
understood and highlighted in the information provided.
This includes both the risk that the cure may fail and, even
if it appears to work initially, that the risk of relapse exists.
Through a good informed consent process…they
would acknowledge that this was a risk and that they
were willing, they went in with their eyes wide open.
(12 = academic)
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Present to the patient the fact that there’ve been “X”
number of people that have been treated and 1, 2 or 9
patients…have actually experienced this problem. The
informed consent form will change so patients will
know that there's a good chance of relapse.
(6 = HIV researcher)
Desperation and its impact on risk assessment
Among the respondents drawn from a patient, community
or activist base, the desperation for a cure was a consistent
theme. Even amongst those who had controlled the virus
with HAART, there is a desire to be cured and to end
dependence on medication. Desperation for a cure could
influence consent processes considerably.
So the ethical concern is will the patients really
understand that; and there's always a risk that the
patients might be so desperate and be willing to try
anything ... even if it’s not in their best interest.
(I = social scientist)
I think for any person if you’re going through
something as life threatening as HIV there’s always
that hope of “I would wake up one day and it’s gone.”
So the mere fact that this might be a cure - that in
itself is hope and that “I could be cured, I could go
back to having a normal life.” (B = academic)
Other respondents, mainly the laboratory re-
searchers, those working on HIV treatment trials and
some of the treating physicians, felt that potential
respondents would take a considered decision. These
respondents felt especially that those who had
controlled the virus using HAART and were consist-
ently adherent may not be willing to risk their
current diagnostic status and protection to participate
in a trial. Although, even in this group, there was an
acknowledgement of the desire to be cured.
People will assess their risks and assess what they
want to do. It’s going to have to be communicated
very well though. (1 = HIV activist)
I suppose there might be a group of patients who
would say, well, you know “I'm living happily on my
ARVs, you know, why rock the boat?” (B = academic)
Options for improving information sharing
A number of ideas on methods of improving information
sharing and encouraging understanding were shared.
There was general agreement for the need to have a
strong community education programme in addition to
individual consent. Options discussed included the use of
pictures and diagrams, or educational videos to aid
problems of literacy and to offer a combined verbal and
visual display.
You would want your two-page summary, but at
the same time it probably isn’t just giving out a
brochure. It would be things like having interactive
seminars; like what they’ve had in terms of
producing a video …and importantly checking
understanding, because that’s often lacking in the
consent process, …seeing how they understand the
risk rather than anything else. So yes, you will
probably spend more time on it than you would
on any normal study. (D = REC member)
I think more use should be made possibly of pictures
rather than words. (B = academic)
Videos would be another way of conveying
information. You know, people – I suppose it might
be, even more so in the current electronic era; that
people's skills with the written word are not that
great. And they're more used to pictures, videos, and
interactive programmes. (B = academic)
Respondents also suggested that behavioural scientists
should make a stronger input into trials so research
could be more easily understandable.
The minute it got medicalised we jumped on and
then we learnt very quickly that actually doing the
medical without the behavioural was folly anyway.
(3 = HIV researcher)
Some respondents from a community advisory board
suggested training people from the community to act as
counsellors and consultants that potential participants
could go and talk to. These community informants
would be fully informed about the study, and could talk
to potential study participants in terms that make sense
to them and reflect community issues. These discussions
could also happen in a less stressful environment than a
research setting.
But people from the community; people whom they
trust…like a social worker…I think – because I mean
she’s – you can, anybody can explain it to her in
English; and she will be able to communicate that to
people. (M = religious leader)
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It would also be useful to conduct a separate, probably
qualitative study, before going into the field to find out
what different people need to know, what current beliefs
exist about HIV and cure and how these may affect
consent, and the capacity of community members to
participate in the study if complicated follow-up
demands are made.
Then you have a community discussion and really see
what people’s thoughts are. If I were you, I would also
do a survey with the community; what do you think
about this research? (N = REC member)
It is also important to improve assessment of how well
participants understood the material. According to
respondents, this assessment should also include a
component for assessing expectations, especially given
the emotions around and desperation for a cure. This
would go beyond the usual test of understanding of the
consent form that is currently conducted in some HIV
studies.
The idea of some sort of questionnaire; be it even a
visual one, to assess patients’ expectations if they were
to be enrolled into a trial; and to validate any score that
might be used as a criterion for entry. (B = academic)
Psychologically I guess you can do some screening, …
what the patient’s motivations are; and see if they
really understand the risks... And to prepare them for
an adverse outcome. (I = social scientist)
A further option raised was to look at consent as a
counselling process, where the potential participants are
taken through the information in a supportive manner
with the research team acting as facilitators to work with
the potential participant to make an informed decision.
This kind of informed consent is just not a process of
informing and educating the person. It’s about ...it’s
actually taking the person through a counselling
process. You really need to be taken through the
issues like why is it important for you to be part of
this research. (1 = HIV activist)
Consent over a longer time period
Respondents spoke about the implications of having
to obtain consent for the extended period of the
study, which may be up to 10 or 15 years, to assess if
the intervention is a sterilizing or functional cure.
Maintaining this relationship over a long trial does
have implications. If conditions change years down
the trial or the participant realises implications of
consent, this has to be taken into account.
You are a participant; you are told things; you haven't
done informed consent in the last five minutes, you've
done informed consent back at some point a few
years ago. You are now three years down in your
relationship with this person and you get told stuff.
(C = social scientist)
Information provision on HIV, the treatment and the
study trial also has to continue over the long-term. As
new information emerges about the treatment or about
HIV, this has to be communicated to participants, espe-
cially if it has to do with their health or risk of a negative
outcome.
Willingness to participate based on trust
Due to the trust participants may place in doctors
and other health professionals and in the scientific
process, they may be willing to place their trust in
the trial without really appreciating the consequences.
This trust must not be abused, so all communication
must be honest and accurate. Consent in this context
does imply a greater dependence on altruism from
participants in making their decisions about whether
to participate. As stated earlier, a cure is not guaran-
teed and many early trials are likely to fail. This must
be communicated, so that participants understand
that their participation is unlikely to bring them an
early benefit. Psychological support should also be
provided willingly and upfront.
They have trust in the system… and I think we
need to be very careful not to abuse that trust.
(W = private health funder)
My experience and my work with people is a question
of trust …That trust is sort of …on a personal level …
they will really open up and they will be willing also
to share their experiences if they feel that they can
trust. (M= religious leader)
This trust has to be maintained throughout long
studies, potentially spanning many years. Therefore,
retraining and reinvesting in the relationship will also
have to occur regularly.
The challenge with informed consent is that it’s an
ongoing process you know so there has always got to
be that rapport so they can keep asking questions.
(T = HIV researcher)
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Discussion
The ambivalence around HIV exceptionalism with re-
spect to HIV cure research is an important finding and a
point of departure in exploring the themes that emerged
from this empirical study. Although obtaining consent
to conduct HIV cure research will be informed by re-
search ethics guidelines and GCP making it no different
from other types of research, most respondents indicated
that some aspects of the consent process for HIV cure
research are different and will therefore require particu-
lar emphasis and consideration. To begin with, consent
processes for HIV cure research are different from con-
sent processes for HIV prevention research and HIV
treatment research. These differences arise due to the
content of information that needs to be shared with po-
tential participants, trial design, interventions, number
of early phase research studies available and follow-up.
Scientific complexity in cure research generally exceeds
the scientific design of prevention and treatment trials
[13]. The concept of eliminating the viral reservoir, for
example, is unique to cure research. While strict adher-
ence to antiretroviral treatment is stressed in treatment
trials, some cure trials may require treatment interrup-
tion. The dissonance between what is preached in clin-
ical care and treatment trials and the messaging in cure
trials creates an ethical challenge [1]. Furthermore, a
homogenous consent process cannot be employed in
HIV cure research due to the heterogeneity inherent in
HIV eradication strategies. Consequently, consent pro-
cesses in HIV cure research would differ in accordance
with the particular cure strategy employed. Some studies
would require analytic treatment interruption requiring
detailed explanations of why and how this will occur,
others may employ a “shock and kill” strategy with po-
tentially toxic drugs aimed at eliminating reservoirs [13].
Use of a therapeutic vaccine aimed at effecting a durable
cure is additionally challenging as patients and potential
research participants are more familiar with preventive
vaccines than therapeutic vaccines. Gene therapy and
bone marrow transplants with HIV resistant donor cells
are far more complex scientifically and will require more
effort at explanation and translation. This is not a simple
matter of HIV exceptionalism. Instead, the requirement
for a more robust consent process is directly linked to
the nature of the science underlying HIV eradication
strategies.
It is therefore not surprising that respondents spoke of
the need to go beyond minimal ethical requirements in
the case of HIV cure research to address some of the
real impacts of HIV at an individual, psychological and
community level. Such ethical approaches to HIV cure
research need to address these particular concerns at the
outset when trials are being designed. At an individual
level, PLHIV have experienced stigma, poor health and
have lost family members and friends. While current
HIV treatments result in longevity, there are costs in
terms of side effects and adherence which, in and of
itself, are constant reminders of illness. Hence, many in-
fected people are desperate to be cured. At the commu-
nity level, there have been huge impacts including death
and mourning, economic breakdown, orphan-hood,
community division and the constant fear of possibly
contracting the disease. So, communities as broad sys-
tems, both geographical and communities defined by
personal characteristics such as men who have sex with
men, sex workers or young women, share a high level of
vulnerability. This vulnerability means that obtaining in-
dividual consent from participants in a trial could easily
occur by a quiet manipulation of the process, offering a
cure for HIV, creating expectation, taking advantage of
the trust in and status of health professionals, especially
doctors, and offering incentives of both money and add-
itional treatment. Any perceived benefits of participation
play a crucial role in decision-making around enrolment,
particularly where the perceived benefits would include
the possibility of being cured of HIV [37]. There are
many emotions attached to a diagnosis of HIV and
rational considerations, such as the potential for risk due
to side effects or the development of resistance due to
treatment interruption, may not weigh in as heavily. This
desperation may lead participants to take excessive risks
[38]. Trial medications may have direct risks in terms of
adverse effects. Some of these will be anticipated from
earlier phase trials and can be explained, but there is the
potential for additional unanticipated adverse effects and
unknown allergic reactions that may arise. With more
radical treatments such as radiation, gene therapy or
shock and kill approaches where HIV is lured out of
reservoirs and then killed, the risks may be even more
difficult to anticipate. Additional risks may occur if the
person is on HAART and has to interrupt treatment, or
if the commencement of treatment is delayed. Participa-
tion may increase rebounding of viral load, and resist-
ance to the treatment used prior to enrolment. There
may also be implications for concomitant treatments
used for co-morbid illnesses and opportunistic infec-
tions, such as tuberculosis and other sexually transmit-
ted infections. Hence the need expressed by respondents
for clear communication of risks and benefits.
The potential for manipulation of trial participants
based on suboptimal risk perception requires a level of
protection and additional oversight from RECs and from
researchers conducting studies. Others have argued,
based on decision-science, that participants should be
allowed to accept research-related risks in keeping
with their personal risk profiles for other aspects of
their lives [39]. While this may be acceptable in
highly educated, empowered communities, it may not
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work in educationally disempowered vulnerable com-
munities in low resource settings. The intersection of
individual good and community good also plays itself
out in terms of a risk-benefit calculation. Dan Wikler
argues that federal research ethics guidelines in the
United States often refer to individual risk versus
community benefit. Yet others calculate risk relative
to individual benefit. The global health value of find-
ing a cure is so substantial that additional individual
risk would almost be justifiable provided participation
is voluntary and fully informed [40]. This view is
expressed in South African research ethics guidelines
where the analysis of risks and benefits needs to
consider participants but community and societal
interests as well [41].
Respondents in this study argued strongly that HIV
research studies should not offer or claim a cure. This
sentiment has been expressed by others. George Annas
refers to “cure research” as an oxymoron [42]. The level
of science currently makes what people envisage as a
cure- a permanent eradication of the existing virus – un-
likely [43]. Sylla et al. similarly found in their study that
respondents “conceived of a cure as eradicating”. Many
participants “did not regard functional cure as an im-
provement over controlling HIV through ART” [22].
Consequently, “cure” research may be best presented as
research that is part of a process towards finding a cure.
This does present a real challenge in the field as the
difference in position is subtle and study staff involved
in recruitment can easily slip into the narrative of cure.
Others have suggested that deliberate use of specific
terms such as “experiment” be adopted to guard against
curative misconception [44]. This is the language that
RECs need to be attentive to in reviewing consent docu-
ments for so-called HIV “cure” studies. The first HIV
cure study conducted in the Western Cape did not use
the word cure in its consent information documents
(personal communication). This is consistent with the
views expressed by respondents who urged caution in
using the word cure in experimental clinical trials.
As argued above, the best defence against curative
misconception is the provision of sufficiently clear and
easily understandable information so that potential
respondents know what they are committing to. This is
more complex than the statement implies. A number of
ideas are presented by respondents for providing this
information including educational videos, cartoons and
pamphlets. This implies that RECs need to ensure that
various consent tools are submitted to enhance under-
standing during the consent process in proposed HIV
cure trials.
This study has highlighted a unique dimension of
consent in the context of HIV cure research. Previous
research has highlighted how participants conceptualise
risks in HIV cure research as having biological, psycho-
logical and social components [26]. HIV cure research
would offer a biological cure only. Healing, as a holistic
construct, embodies biological, psychological and social
components in restoring patients to health. There is
therefore a need to reframe biological cure as a compo-
nent of healing, and additional attention must be paid to
the psychological and social elements to complete the
process of healing on the path to HIV elimination. This
has implications for how the REC reviews both the
protocol and consent process for HIV cure research.
Researchers ought to be required to submit a plan to the
REC outlining how psychological and social harm will be
mitigated in the context of high risk HIV eradication
trials involving vulnerable populations desperate for a
cure. In addition to science translation to facilitate
understanding of consent information, respondents
referred to assessment of psychological readiness to con-
sent to participate in cure research. This would ensure
that desperation for a cure did not result in underesti-
mating the risks involved. Furthermore, in the event of
failure of an intervention to lead to cure, psychological
support and counselling would be necessary. These con-
cerns are echoed in the work of Sylla et al. where partici-
pants were “distrustful about viral rebound potential”
and the “accompanying psychological distress” [22]. This
could occur a few years post trial and unlike other
studies, long-term consent processes and support ser-
vices would be necessary. While ideal, it may not always
be practical to have a psychologist involved in a clinical
trial. In this case other counsellors, adequately trained to
address the psychological well-being of trial participants
and to provide counselling in the event of negative trial
results for cure interventions. RECs would need to
request evidence of the availability of such counsellors
both during a cure trial and after the study.
With long-term research studies, participant education
may need to occur on a phased basis. This would require
the development of decision-making tools so a decision
can be broken down into components such as safety of
the intervention, ancillary care that would be provided,
benefits to the person, benefits to society and commu-
nity, nature of treatment, and how the intervention
works. By presenting all of these components separately
it may be easier for the potential participants to develop
a clearer picture of what the trial is about.
Another core consideration in the type of research
anticipated here is that the consent process has to be
embedded in a long-term relationship between the
research team and participants. This has implications for
consent information. It has to be clear at the outset that
the potential participant is being recruited for a trial that
will include ongoing monitoring that may last 10 years
or more. This is not unusual as many cohort studies
Moodley et al. BMC Medical Ethics            (2019) 20:9 Page 9 of 11
extend for much longer, but in the case of HIV cure
research there are potentially risky drugs involved,
coupled with high levels of expectation. RECs would
have to request follow-up consent templates in addition
to the enrolment consent form. One consideration here
would be to have the participants sign an annual
re-consent to their participation in the study. This would
be in line with the study having to request renewal of
REC approval annually. In the event that some “cure”
trials are regarded as “high risk”, more frequent REC
monitoring (such as 6 monthly progress reports) may be
indicated.
This study sought to elicit a broad range of perspec-
tives from multiple HIV stakeholders in three major
regions of the country. Consequently, the diverse views
expressed by participants have made a meaningful con-
tribution to this emerging field of study in South Africa.
An important limitation however is that HIV cure re-
search has not started in earnest in South Africa and
hence our discussions revolved around hypothetical tri-
als. Perceptions may change when the prospect of cure
becomes a reality. Furthermore, only one interview was
conducted per participant due to sample size and time
constraints. The potential for further longitudinal studies
exists. While the absence of guidelines on the ethics of
HIV cure research is a challenge, empirical research
from this study has the potential to inform future guide-
line development.
Conclusion
Against the backdrop of HIV prevention and treatment
trials in South Africa over the past three decades, HIV
cure research is generally perceived to require unique
consent approaches. While significant efforts would need
to be invested in science translation to maximise under-
standing of trial procedures, risks and the need for
long-term follow-up, the psychological dimension of
cure should not be underestimated. Beyond an under-
standing of cure science, the emotional impact of HIV
resulting in desperation, hope and expectation, advances
the discourse from cure to healing. Consequently, the
consent process for cure research would need to be sig-
nificantly enhanced to include psychological support and
counselling. Ethics review requirements for consent in
HIV cure research will need to examine the language in
consent documents more closely to ensure that eradica-
tion messaging is not misleading. Consent requirements
may need to be augmented to accommodate additional
measures such as educational tools to enhance participant
understanding and to ensure psychological well-being
during recruitment, enrolment and long-term follow-up.
Debriefing of trial participants would be necessary at
regular intervals. Re-consent in long-term studies, more
frequent progress reports and post-approval monitoring
of HIV eradication studies are strongly recommended.
Finally, the development of a specific guidance document
for HIV cure research would assist and expedite the REC
review process to enable complex scientific eradication
research to proceed to the mutual benefit of researchers,
participants, communities and societies.
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